Previous 10 | Next 10 |
Teva Pharmaceutical Industries ( TEVA -4.2% ) slumps on modestly higher volume. Shares are now exchanging hands at the lowest prices in 19 years. The stock continues to fight pricing headwinds, the continued erosion of Copaxone sales (down 56% in Q1) and its potential exposure from opioid ...
Let's spell Biogen Buy-o-Gen. Indeed, BIIB seems increasingly appealing at current price. The biotech focuses on discovering, developing, and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets various products for multiple sc...
This article is part of a series that provides an ongoing analysis of the changes made to Ole Andreas Halvorsen’s 13F stock portfolio on a quarterly basis. It is based on Viking Global’s regulatory 13F Form filed on 05/15/2019. Please visit our Tracking Ole Andreas Halvorsen...
Agilent (NYSE: A ) initiated with Overweight rating and $83 (18% upside) price target at Piper Jaffray. More news on: Agilent Technologies, Inc., Danaher Corporation, Teleflex Incorporated, Healthcare stocks news, Stocks on the move, , Read more ...
In a unanimous 14 - 0 vote, the FDA's Antimicrobial Drugs Advisory Committee recommends approval for the combination of pretomanid, bedaquiline and linezolid (BPaL regimen) for the treatment of adults with pulmonary extensively drug resistant (XDR) or treatment-intolerant or nonresponsive mu...
A Perfect Storm Of Negative Headlines And Analyst Downgrades Has Created A Buying Opportunity After an already severe punishment in the past couple of weeks, Teva Pharmaceutical Industries ( TEVA ) took another beating of nearly 10% on May 30, after Jason Gerberry, an analyst at Bank of ...
While generic companies are embroiled in more price fixing investigations , some opioid scandals , and other mishaps, another presence has started encroaching on their sales. As mentioned in our previous article, which can be found here , Civica RX (Civica) will likely have a large impact o...
Novartis ( NVS ) announced that it had achieved positive results in two phase 2 studies using IND/GLY/MF to treat patients with asthma. IND/GLY/MF, also known as QVM149, was superior to the standard of care in both of these studies. In addition, on the safety front, the company's drug had a ...
This article is part of a series that provides an ongoing analysis of the changes made to John Paulson's 13F stock portfolio on a quarterly basis. It is based on Paulson's regulatory 13F Form filed on 05/15/2019. Please visit our Tracking John Paulson's Pau13lson & Company Portfolio ser...
This article highlights the worst performing foreign stocks year to date 2019 through data as of May 21. The YCharts equity screening tool database counts 2,384 foreign stocks that either trades as an American Depository Receipt "ADRs," is primarily listed on a U.S. exchange, or is a foreign...
News, Short Squeeze, Breakout and More Instantly...
Mylan Announces Third Quarter 2020 Financial Results and Looks Ahead to the Launch of Viatris Inc. PR Newswire HERTFORDSHIRE, England and PITTSBURGH, Nov. 6, 2020 HERTFORDSHIRE, England and PITTSBURGH , Nov. 6, 2020 /PRNewswire/ -- Mylan N.V. (NASDAQ...
Our experts issued a rare "Double Down" Buy alert on this one stock... Learn more. A long-awaited deal will soon be done. Pfizer (NYSE: PFE) and Mylan (NASDAQ: MYL) announced last week that the U.S. Federal Trade Commission has approved the planned merger of Pfizer's...
Mylan Announces Appointment of Experienced Pharmaceutical Executive Bill Szablewski as Head of Capital Markets for Viatris PR Newswire HERTFORDSHIRE, England, and PITTSBURGH, Nov. 2, 2020 HERTFORDSHIRE , England, and PITTSBURGH, Nov. 2, 2020 /PRNews...